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mainly two syndromes: thrombotic thrombocytopenic
Background. The pentad of thrombocytopenia, hemolytic purpura (TTP) and the hemolytic uremic syndrome anemia, mild renal dysfunction, neurologic signs, and fever, (HUS) . TTP consists of microangiopathic hemolytic aneclassically characterizes the syndrome of thrombotic thrombomia and thrombocytopenia associated with platelet agcytopenic purpura (TTP). TTP usually occurs in adults as an gregation in the microcirculation responsible for ischacquired form but a congenital form in children has also been emic manifestations [1] . The pathophysiology of TTP described. In the latter case, the initial presentation is often with neonatal jaundice and thrombocytopenia. The disorder involves occlusion of small arterioles and capillaries by may subsequently take a relapsing course. Deficiency of a replatelet plugs containing high quantities of Von Willecently identified novel metalloprotease, the von Willebrand brand factor (vWF) [2] . These platelet-rich microthrombi factor (vWF)-cleaving protease, originating from mutations in are observed in the small vessels of various organs. vWF the ADAMTS13 gene plays a major role in the development is a large glycoprotein essential for platelet adhesion and of TTP. aggregation, especially at the high shear stress-associated
Methods. Blood for DNA analysis was collected from six unhemodynamic conditions of the microcirculation [3] . vWF related TTP families, consisting of nine patients from four different countries, and was screened for mutations in the ADAMTS 13 is synthesized as a large precursor protein that consists regulator of the size of the multimers is a specific metalloOnly one of the nine patients had a decreased glomerular protease [4, 5] , which cleaves the peptide bond between filtration rate (GFR) with proteinuria and hematuria. Another Y842-M843 of vWF mature subunit [6] and prevents the patient had epileptic seizures.
interaction of the largest multimers with platelets. In Conclusion. We confirm that deficiency of ADAMTS13 is plasma of patients with TTP, unusually large multimers a molecular mechanism responsible for familial TTP. An early diagnosis allows prophylactic treatment with fresh plasma infuof vWF (UlvWF) have been observed [7] .
sions.
In 1998, a major breakthrough in the understanding of TMA pathology occurred with the discovery of a deficient activity of vWF-cleaving protease (either constitu-fied mutations in the of ADAMTS13 gene as the underlying molecular mechanism responsible for familial TTP. 
a Patient 2 and patient 7 are siblings, as well as patient 4 and patient 8 and patient 6 and patient 9, respectively b Patient 1. Brother died immediately after birth. The autopsy revealed widespread thrombi, especially in the myocard, adrenal gland, kidney, and lungs c Prophylactic treatment with hemate (ϭ vWF/factor VIII concentrate) in these patients is described previously [25, 26] . These patients were treated with freshfrozen plasma before the treatment with hemate started.
ADAMTS13 is a newly identified member of the
Mutation analysis ADAMTS family of protein-cleaving proteinases. CleavGenomic DNA was extracted by a salting out proceage of endothelial cell derived ULvWF multimers by dure from peripheral blood lymphocytes [13] . Sequence ADAMTS13 is a rapid physiologic process that occurs analysis was by polymerase chain reaction (PCR) and on the endothelial cell surface. direct cycle sequencing. Cycle sequencing was carried out In this article, we report the identification of eight by the Dye-deoxy Terminator method, using the ABI ADAMTS13 mutations in a cohort of nine patients, inPrism 377 sequencer (PE Applied Biosystems, Nieuwecluding three affected sibling pairs from different geokerkaan de Ijssel, The Netherlands) following standard graphical origins. The presumptive effects of these mutaprocedures [14] . Primers were from Life Technologies tions on the function of the ADAMTS13 protein are (Breda, The Netherlands). They were designed to permit analyses of complete exons, including intron boundaries, discussed. We did not observe a hotspot for mutations according to the public available sequence (AY 055376). in the ADAMTS13 gene. Finally, our findings suggest
The primer sequences and the PCR protocols are availgenetic heterogeneity in familial TTP. able upon request. To confirm the mutations, restriction enzyme analysis with BsaJI (for exon 7 D235H), AlwNI METHODS (for exon 7 6 bp deletion), RsaI (for exon 8), MboII (for TTP families exon 9) and AluI (for exon 12) was performed according to the manufacturer's recommendation. The segregation Our study cohort consisted of nine children. All paof mutations has been studied in members of the family tients were diagnosed as TTP. The clinical diagnosis of of patients 1, 2, 3, 4, and 6. TTP was based on the presence of hemolytic anemia with fragmented erythrocytes, and thrombocytopenia, which could be accompanied by fever and decrease of RESULTS GFR. All patients demonstrated a lack of vWF-cleaving Clinical and biochemical data protease. The assay of vWF-cleaving protease activity Clinical data were available for nine patients, conwas performed as described previously [12] . Briefly, disisting of three sibling pairs and three cases with no luted citrated plasma was activated by barium chloride.
familial history of TTP. The diagnosis of TTP was made This activated plasma was added to protease-free vWF.
between the age of 4 and 64 months. Seven patients The reaction was stopped by addition of ethylenedi-(including two affected sibling pairs) had symptoms of aminetetraacetic acid (EDTA). The extent of vWF degjaundice or thrombocytopenia during the neonatal peradation was assayed by multimer analysis using sodium riod, while three required neonatal exchange transfusion dodecyl sulfate (SDS)-electrophoresis in 1.4% agarose (Table 1) . These early symptoms are likely to represent gels. Following electrophoresis, the proteins were electhe first symptoms of TTP. In Table 2 the current situatrotransferred to nitrocellulose, and vWF was visualized tion of the children is described. Surprisingly only one with peroxidase-conjugated rabbit antibodies against huof the patients had a decreased glomerular filtration rate man vWF. Patients 1, 2, and 7 were tested for vWF-(GFR). cleaving protease in our hospital. Patients 3, 6, and 9
Mutation detection in the ADAMTS13 gene were tested by M. Furlan [4] with the same technique. Patients 4, 5, and 8 were tested for the deficiency at the Human genomic DNAs from six TTP families, including nine patients (three affected sibling pairs), have been hospital of origin. screened for mutations in the ADAMTS13 gene by PCR mutation in the other allele of patient 4 (and patient 8) predicts a truncated ADAMTS 13 protein. The homozyin combination with DNA sequencing of 29 exons that encode the complete coding region. A total of eight gous deletion in patient 5 and the homozygous insertion in patient 6 (and patient 9) result in a frameshift and a different mutations have been identified consisting of four missense mutations, two deletions, one insertion, and premature stop codon. The remaining four mutations all result in nonconservative amino acid substitutions and one nonsense mutation ( Fig. 1 and Table 3 ). All mutations are novel molecular variants of the ADAMTS13 gene. In all occur at positions that are perfectly conserved between the human and mouse genes. The parents of the addition, the mutations are spread over the gene (Fig. 2) .
In our total study group of six unrelated families, four patients in families 1, 2, 3, 4, and 6 were all heterozygous carriers of one mutant ADAMTS13 allele. All TTP pacarry homozygous ADAMTS13 mutations (patients 1, 2, 5, and 6) and two are compound heterozygotes (patients 3 tients displayed homozygous or compound heterozygous mutations in the ADAMTS13 gene. In addition, in all and 4). During the mutational analyses in the ADAMTS13 gene, 10 polymorphisms were observed. These appeared patients with homozygous or compound heterozygous mutations clinical symptoms were evident. Heterozygous to be present in control alleles with variable frequency and have previously been described at NCBI (http:// carriers were without symptoms. Fifty control chromosomes (one hundred alleles) were tested for the presence www.ncbi.nlm.nih.gov).
The six base pair deletion observed in one allele of of the four missense mutations that have been identified in our study group. All appeared to be absent in these patient 4 (and patient 8) caused the removal of two highly conserved amino acids of the ADAMTS 13 protein. The control chromosomes. function. The follow-up of our patients is reassuring, even when no prophylactic plasma infusions were given. This is certainly an unexpected finding. Only one patient had a decrease of GFR with proteinuria and microscopic events [19] . Among the ADAMTS13 mutations identified in our DISCUSSION TTP cohort, three are likely to have a deleterious effect on the function of ADAMTS13. The nucleotide deletion The hypothesis that vWF-cleaving protease deficiency (patient 5), the nonsense mutation (patients 4 and 8) and is central to the pathogenesis of familial TTP has recently the insertion (patients 6 and 9) will cause premature termibeen supported by the identification of several mutations nation of translation and result in truncated ADAMTS13 in the ADAMTS13 gene in patients with familial TTP proteins. Half of the mutations detected in our familial [11, 15] . In the present study, the specific involvement TTP cohort, however, are amino acid substitutions. Our of this protease in the etiology of this disorder is further data together with the results of previous studies [11, 15] substantiated by the finding of eight novel mutations in indicate that 15 out of a total of 23 identified mutant a cohort of six unrelated TTP families from different ADAMTS13 alleles are missense mutations. These mutageographic origins.
tions are inferred to be pathogenic when they substitute Clinical data of the six patients and three affected highly conserved amino acids, which in view of their siblings revealed important information. The diagnosis conservation through evolution are presumed to be of of TTP was made between 4 and 64 months of age. Seven functional importance. All four missense mutations dehad, however, already symptoms in the neonatal period. tected in our TTP cohort are substitutions of strongly Interpretation of clinical data in patient 1 is complicated conserved into nonconservative amino acids and were by an associated streptococcal septicemia during the neonot found in 50 control chromosomes. Therefore, it is natal period. In the neonate vWF-cleaving protease level likely that the majority of these missense mutations are is decreased (average 52%; range, 25% to 118%) [16] , indeed harmful mutations and not innocuous polymorbut still in the range allowing cleavage of the large phisms. However, to prove that these amino acid substimultimers of vWF [10] . UlvWF multimers are present tutions can indeed result in impairment or loss of function in the majority of the plasma of the fetus and full-term will require study of the effect of individual mutations and preterm neonates. These UlvWF multimers disapon vWF cleavage in a functional expression system [15] . pear within a few weeks after birth [17] . UlvWF multimers, By expression analysis in HeLa cells Kokame et al [15] which are under normal circumstances not present in could demonstrate that vWF-cleaving protease conchildren and adults, contribute to platelet aggregation taining two specified mutations were not secreted from and hemostasis in the normal fetus and neonate. Plasma cells, while in the case of two other mutations, mutants vWF in neonates is more multimerized than in adults were normally secreted but showed minimal activity. and this explains the increased platelet deposition on These findings suggest that the clinical symptoms of the subendothelium under flow conditions [18] . The possibilpatients will be heterogeneous. ity exists that in patients with a congenital form of TTP,
The eight mutations detected in our study were presthere are even more UlvWF multimers in the fetal and ent in TTP patients from different geographic regions. neonatal phase than in normal fetuses and neonates.
This indicates that a common ancestor is unlikely. Possibly these UlvWF multimers cause thrombi and are Of note, we were unable to identify a mutant allele thus responsible for the first signs of TTP. The manifestain another patient, despite documented vWF-cleaving tion of TTP in our patients after a certain honeymoon period suggests a physiologic maturation of the platelet protease deficiency. This patient has a typical history of of congenital TTP is important as symptomatic episodes
